Galmed Pharmaceuticals develops therapeutics for inflammatory diseases, focusing on metabolic conditions and leveraging drug research and development.

Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 19, 2024 4:33 PM	d0608bb7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 19, 2024 5:18 PM	a9595837
company summary	general
signals	general	Sep 19, 2024 4:33 PM	384c386e
crunchbase trigger	general	Nov 27, 2024 12:50 PM	2d2a3917
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 19, 2024 4:33 PM	0ff2ea40
news basic	general	Sep 19, 2024 4:33 PM	9986c160
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:GALMEDPHARMA

Galmed Pharmaceuticals

Last Close

2.80

22/11 21:00

Market Cap

1.82M

Beta: -

Volume Today

16.15K

Avg: -